Bristol-Myers Squibb Company
Date
re: Proposed settlement of infringement litigation with Teva Pharmaceuticals involving sharing of the exclusivity period for the drug Paraplatin.
Displaying 3941 - 3960 of 4596
Apr16
Health Care Information and Competition conference
This quasi-academic conference, organized by Stanford health economist Dan Kessler, brought together academics and health policy makers to examine the production of and use of health care market...
Apr15
Ideas into Action: Implementing Reform of the Patent System
-
The FTC, the National Academy of Sciences (NAS), and the Berkeley Center for Law and Technology co-sponsored a conference to address patent reform and how it might be implemented. The event brought...
FTC to Co-Sponsor Conference on Patent System Reform
Date
On April 15 and 16, 2004, the Federal Trade Commission, the National Academy of Sciences (NAS), and the Berkeley Center for Law and Technology will co-sponsor a conference to address patent reform and...
FTC Testifies on "Market Forces, Anticompetitive Activity, and Gasoline Prices"
Date
Testifying today on behalf of the Federal Trade Commission before the Subcommittee on Antitrust, Competition Policy, and Consumer Rights of the Senate Judiciary Committee, General Counsel William...
RHI AG, in the Matter of
The complaint alleged that RHI violated various provisions of an FTC order issued in 2001. According to the complaint, the 2001 order was issued pursuant to a 1999 consent agreement with RHI that followed the FTC’s investigation of RHI’s acquisition of Global Industrial Technologies, Inc., and resolved concerns that the acquisition would decrease competition in North American markets for refractory bricks used to line steel-making equipment. The order, as drafted in 1999, required RHI to divest to Resco Products, Inc. two refractories plants and other assets in Canada and the United States in a manner set out in contracts between Resco and NARCO, an RHI subsidiary. However, before the order became final, the FTC determined, in 2000, that NARCO failed to divest all of the requisite assets to Resco. The complaint also charged that NARCO manufactured refractory bricks in violation of a patent license that was part of the order, and in violation of specific order language. Finally, the complaint asserted that NARCO modified the settlement agreement with Resco without FTC approval. Under the terms of the final judgment, RHI agreed to pay a civil penalty of at least $650,000 for the violations and to conduct asbestos remediation at a divested plant.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0210105
Docket Number
C-4005
FTC Staff: New York Direct Shipment of Wine Bills Would Promote E-commerce and Consumer Welfare
Date
In response to requests from three New York state legislators, the staffs of the Federal Trade Commission’s Office of Policy Planning, Northeast Regional Office, and Bureaus of Competition, Consumer...
FTC: E-commerce Increases Choice and Convenience for Contact Lens Wearers
Date
The Federal Trade Commission today released a staff report concluding that e-commerce offers consumers greater choices and more convenience in the contact lens market. This staff report is part of a...
FTC Staff: Kansas Bill Is Likely to Deter Gasoline Price Cuts
Date
In response to a request from Kansas State Senator Les Donovan, the staff of the Federal Trade Commission’s Office of Policy Planning, Bureau of Competition, and Bureau of Economics filed comments...
Feb17
FTC/DOJ Joint Workshop on Merger Enforcement
-
This three-day workshop brought together prominent practitioners, academics and enforcement officials to discuss the Horizontal Merger Guidelines. The workshop explored state-of-the-art application of...
Administrative Law Judge Dismisses FTC Complaint Against Rambus
Date
Chief Administrative Law Judge Stephen J. McGuire today issued his initial decision and order in the matter of Rambus, Inc. The order states "Accordingly, Complaint Counsel having failed to sustain...
Tenet Healthcare Corporation and Frye Regional Medical Center, Inc.
A consent order prohibits Frye Regional Medical Center, Inc., an acute care hospital in Hickory, North Carolina, and its parent company Tenet Healthcare Corporation from entering into any agreement to negotiate fees on behalf of any physician practicing in four North Carolina counties and from refusing to deal with insurance companies and other payers. Also refer to related administrative complaint issued to Piedmont Health Alliance. This settlement is the first case in which the Commission has named a hospital as a participant in an alleged physician price-fixing conspiracy.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0210119h
General Electric Company, In the Matter of
A final consent order settled antitrust concerns stemming from General Electric Company’s proposed acquisition of Agfa-Gevaert N.V.’s nondestructive testing business. According to the complaint issued with the consent order, the transaction as proposed would have eliminated competition in the United States markets for portable flaw detectors, corrosion thickness gages, and precision thickness gages - equipment used to inspect the tolerance of materials without damaging them or impairing their future usefulness. The consent order requires General Electric to divest its worldwide Panametrics Ultrasonic NDT business to R/D Tech, Inc. within 20 days after the transaction is completed.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0310097
Docket Number
C-4103
FTC Staff Concludes that Alabama Motor Fuels Marketing Act Restricts Competition
Date
The Federal Trade Commission’s Office of Policy Planning, Bureau of Competition, and Bureau of Economics have sent a letter to Alabama House of Representatives Speaker Pro Tempore, Demetrius C. Newton...
Announced Actions for January 13, 2004
Date
Commission approval of petition to reopen and modify FTC consent order: The Commission has approved a petition from Wright Medical Technology, Inc. (Wright) to reopen and modify a 1994 consent order...
FTC Closes its Investigation of Genzyme Corporation's 2001 Acquisition of Novazyme Pharmaceuticals, Inc.
Date
By a 3-1-1 vote, the Federal Trade Commission today closed its investigation into Genzyme Corporation's (Genzyme) 2001 acquisition of Novazyme Pharmaceuticals, Inc. (Novazyme). At the time of its...
Memorial Hermann Health Network Providers
Memorial Hermann Health Network Providers settled charges that it negotiated fees and other services for medical care provided by its member physicians in the Houston, Texas area in an effort to obtain higher fees and more advantageous terms. According to the complaint these alleged price fixing practices increased costs for consumer, employers, and health plans.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0310001
Koninklijke DSM N.V., Roche Holding AG, and Fritz Gerber, In the Matter of
The FTC charged that, as proposed, DSM's purchase of RV&FC would have a significant adverse effect on competition in the worldwide market for phytase. Phytase is an enzyme added to certain animal feed to promote the digestion of nutrients necessary for livestock production. According to the complaint, absent relief, the transaction would lead to DSM being part of alliances that supply more than 90 percent of the $150 million phytase market worldwide. A consent order permitted DSM N.V. to acquire the Vitamins and Fine Chemicals Division of Roche Holding AG but requires DSM to divest its phytase business to BASF AG.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0310064
Docket Number
C-4098
Displaying 3941 - 3960 of 4596